background
respiratori
syncyti
viru
rsv
infect
major
caus
bronchiol
infant
risk
factor
develop
asthma
allerg
asthmat
suscept
rsv
infect
viral
exacerb
sinc
effect
corticosteroid
treat
rsv
infect
controversi
test
fluticason
propion
fp
salmeterol
sal
alon
versu
fp
plu
sal
fp
rsvinduc
airway
inflamm
mice
sensit
challeng
ovalbumin
ova
infect
rsv
follow
infect
treat
fp
sal
fp
intranas
airway
hyperreact
ahr
inflamm
rsv
titer
examin
group
treat
fp
show
significantli
lower
ahr
compar
group
treat
fp
sal
alon
group
treat
fp
alon
show
slightli
decreas
nonsignific
ahr
compar
control
treatment
fp
result
signific
decreas
percentag
eosinophil
neutrophil
bronchoalveolar
lavag
fluid
lung
patholog
compar
fp
sal
fp
alon
decreas
eosinophil
neutrophil
lymphocyt
sal
alon
decreas
eosinophil
neutrophil
lymphocyt
fp
treatment
mice
infect
rsv
absenc
allergen
sensit
result
decreas
rsv
titer
lung
reduct
neutrophil
compar
fp
sal
conclus
togeth
result
indic
fluticason
combin
salmeterol
effect
treatment
decreas
airway
hyperreact
inflamm
either
alon
allergensensit
rsvinfect
mice
asthma
chronic
lung
diseas
two
distinct
featur
airway
inflamm
airway
hyperrespons
associ
viral
upperrespiratori
infect
uri
exacerb
asthma
report
commonli
identifi
virus
studi
includ
rhinoviru
coronaviru
influenza
viru
respiratori
syncyti
viru
rsv
rsv
predomin
caus
uri
infant
year
age
infect
may
result
bronchiol
risk
factor
asthma
rsv
may
constitut
earliest
trigger
develop
thelper
type
domin
immun
respons
hallmark
immunopatholog
allerg
subject
includ
asthmat
also
rodent
model
uri
caus
decreas
peak
flow
lag
behind
upper
airway
symptom
day
subject
one
studi
report
two
day
lag
peak
flow
reduct
combin
therapi
involv
longact
agonist
inhal
corticosteroid
ic
emerg
effect
asthma
manag
strategi
control
persist
asthma
combin
salmeterol
sal
fluticason
propion
fp
found
superior
either
alon
combin
also
significantli
effect
montelukast
plu
fp
monotherapi
inhal
budesonid
increas
effect
fp
attribut
increas
activ
transloc
nucleu
glucocorticoid
receptor
howev
effect
drug
viral
exacerb
allerg
asthmat
studi
conclus
cochran
review
avail
control
trial
ic
children
histori
mild
episod
viral
wheez
high
dose
ic
partial
effect
treatment
mild
episod
viral
wheez
childhood
sinc
uri
induc
exacerb
may
specif
valu
reduc
exacerb
vitro
studi
pseudomona
aeruginosa
infect
combin
fp
sal
reduc
infect
preserv
ciliat
cell
greater
degre
either
alon
suggest
synergi
two
agent
asthma
exacerb
children
associ
viral
infect
earli
intervent
combin
therapi
benefici
effect
viral
asthma
exacerb
sinc
virusinduc
exacerb
accompani
airway
inflamm
reason
combin
steroid
agonist
might
provid
protect
sever
rsv
infect
ensu
asthma
exacerb
hypothesi
test
mous
model
allergen
sensit
rsv
infect
use
ova
allergen
mice
chronic
acut
sensit
ova
rsv
infect
treat
fp
sal
two
togeth
fp
airway
hyperreact
ahr
pulmonari
inflamm
measur
five
day
infect
result
show
combin
fp
sal
provid
signific
protect
term
airway
hyperreact
pulmonari
inflamm
compar
either
alon
femal
balbc
mice
week
age
obtain
charl
river
hous
pathogenfre
condit
univers
south
florida
vivarium
treatment
protocol
approv
usf
institut
anim
care
use
committe
iacuc
strain
human
rsv
american
type
cultur
collect
manassa
va
propag
cell
american
type
cultur
collect
grown
eagl
minim
essenti
medium
gibco
fb
maximum
cytopath
effect
cell
harvest
medium
suspens
clarifi
centrifug
g
min
result
supernat
layer
onto
glycerol
gradient
centrifug
g
hr
pellet
contain
viru
resuspend
precool
buffer
mm
hepe
ph
mm
mgso
mm
nacl
store
aliquot
liquid
nitrogen
viral
titer
determin
standard
plaqu
assay
combin
immunostain
rsv
mice
infect
light
anesthesia
intranas
inocul
rsv
pfu
experi
singl
rsv
infect
use
therapeut
regimen
mice
sensit
intraperiton
inject
ip
ova
day
intranas
administr
ova
day
day
mice
infect
rsv
day
day
treat
daili
fluticason
fp
propion
salmeterol
sal
two
combin
fp
per
mous
fp
sal
obtain
glaxosmithklin
airway
hyperreact
ahr
measur
day
day
anim
sacrif
prophylact
experi
mice
sensit
intraperiton
inject
ip
ova
day
intranas
administr
ova
day
day
mice
infect
rsv
day
day
mice
treat
daili
fp
sal
two
combin
fp
per
mous
day
mice
reinfect
rsv
challeng
ova
ahr
measur
day
day
mice
sacrif
bal
fluid
lung
spleen
taken
experi
repeat
least
twice
ahr
express
enhanc
paus
penh
measur
unrestrain
mice
whole
bodi
plethysmographi
buxco
troy
ny
group
mice
n
expos
min
nebul
pb
establish
baselin
increas
concentr
mgml
nebul
methacholin
mch
sigma
st
loui
mo
pb
challeng
done
min
follow
record
penh
min
penh
valu
averag
express
mch
concentr
percentag
pb
baselin
read
lung
lavag
use
pb
bal
fluid
kept
process
bal
cell
centrifug
onto
microscop
slide
cytospin
shandon
stain
use
kit
fisher
eosinophil
neutrophil
lymphocyt
count
differ
field
differ
slide
group
blind
fashion
lung
section
stain
hematoxylin
eosin
h
e
inflamm
assess
disrupt
denud
epitheli
layer
infiltr
monocyt
lymphocyt
perialveolar
region
lung
section
also
stain
antibodi
celladhes
molecul
goblet
cell
marker
marker
santa
cruz
biotech
santa
cruz
ca
mice
sacrif
singlecel
suspens
prepar
spleen
cultur
hr
dmem
fb
splenocyt
incub
ovaco
plate
h
treat
golgistop
hr
block
secret
cytokin
cell
surfacestain
research
diagnost
flander
nj
subject
intracellular
stain
antibodi
r
system
minneapoli
mn
cell
analyz
flow
cytometri
gate
cell
percentag
cell
secret
respect
cytokin
shown
mice
sacrif
lung
lavag
pb
aliquot
bal
fluid
store
assay
concentr
bal
measur
elisa
use
kit
r
system
minneapoli
mn
result
express
pg
per
ml
bal
fluid
lung
section
process
detect
apoptosi
use
fluorometr
tunel
system
assay
kit
promega
dewax
section
fix
permeabl
incub
termin
deoxynucleotidyl
transferas
label
dna
end
fitcdutp
stain
section
photograph
fluoresc
microscop
data
express
mean
sem
comparison
two
differ
group
student
test
use
differ
group
consid
signific
p
mice
sensit
ova
day
ip
day
day
infect
pfu
rsv
day
treat
fp
sal
fpsal
combin
fp
ahr
measur
penh
day
fig
day
mice
sacrif
bal
done
differenti
cell
count
perform
bal
fluid
fig
lung
section
stain
h
e
examin
histopatholog
fig
mice
treat
fp
fp
sal
show
reduc
eosinophil
number
chang
neutrophil
saltreat
mice
show
increas
number
lymphocyt
combin
therapi
result
signific
reduct
eosinophil
number
well
lung
inflamm
compar
treatment
lung
allergensensit
rsvinfect
mice
exhibit
cellular
infiltr
mnc
eosinophil
fig
mice
sensit
ova
ip
day
day
day
mice
infect
rsv
pfu
day
day
mice
treat
fp
fp
day
mice
reinfect
rsv
challeng
ova
ahr
measur
day
lower
fpstreat
mice
treat
fp
sal
alon
fig
day
mice
sacrif
bal
fluid
taken
analyz
lymphocyt
eosinophil
neutrophil
differenti
stain
treatment
fp
reduc
number
eosinophil
neutrophil
compar
either
drug
alon
fig
lung
section
show
extens
epitheli
disrupt
cellular
infiltr
case
rsv
exposur
without
drug
treatment
fp
alon
reduc
patholog
somewhat
combin
fp
significantli
effect
fig
result
show
fp
significantli
attenu
ahr
inflamm
seen
decreas
eosinophil
lymphocyt
reduc
perialveolar
damag
compar
control
group
mice
treat
fp
alon
fp
effect
fp
sal
alon
prevent
ahr
lung
inflamm
figur
fp
effect
fp
sal
alon
prevent
ahr
lung
inflamm
mice
sensit
ova
infect
rsv
describ
method
day
mice
treat
daili
fp
sal
fp
ahr
measur
day
day
mice
sacrif
bal
cell
differenti
perform
macrophag
mac
eosinophil
eo
neutrophil
neut
lymphocyt
lym
b
h
e
stain
lung
section
examin
histopatholog
c
result
shown
one
repres
experi
two
determin
effect
fp
therapi
tcell
cytokin
secret
mice
ovasensit
infect
rsv
treat
fp
sal
fp
mice
sacrif
drug
treatment
splenocyt
examin
cytokin
product
intracellular
cytokin
stain
fig
b
cell
stimul
panel
ova
panel
b
fp
increas
number
cell
produc
sal
increas
cell
produc
wherea
fp
decreas
number
cell
produc
lung
epitheli
cell
respond
inflammatori
cytokin
express
specif
cell
marker
intracellular
adhes
molecul
mucin
gene
fig
show
result
immunohistochem
analysi
mous
lung
section
rsv
infect
increas
express
mucin
wherea
treatment
fp
decreas
express
compar
control
mice
anoth
correl
lung
inflamm
infiltr
lymphocyt
perialveolar
tissu
marker
use
stain
lung
section
sal
fp
appear
stimul
infiltr
cell
type
lung
lower
panel
fig
previou
work
lab
document
apoptosi
lung
cell
consequ
ovainduc
inflamm
ovasensit
mice
sought
determin
effect
fp
sal
combin
apoptosi
mice
ovasensit
rsvinfect
treat
variou
drug
combin
end
treatment
sacrif
lung
remov
section
examin
apoptosi
use
tunel
termin
deoxynucleotidyl
transferas
nick
endlabel
assay
fig
show
repres
experi
apoptosi
induc
popul
cell
lung
ovasensit
rsvinfect
mice
extent
apoptosi
reduc
treatment
fp
sal
especi
fp
two
group
mice
sensit
ova
ip
prophylact
treat
fp
sal
fp
prior
infect
rsv
three
day
infect
sacrif
lung
remov
one
group
mice
homogen
titer
rsv
determin
plaqu
assay
bal
fluid
taken
second
group
analyz
elisa
decreas
burden
viru
lung
tissu
fpstreat
mice
match
increas
secret
bal
fluid
fig
increas
product
could
least
part
account
reduct
rsv
titer
goal
studi
determin
combin
corticosteroid
longact
effect
reduc
rsvinduc
asthma
exacerb
either
drug
alon
demonstr
reduct
lung
inflamm
ovaallerg
mice
infect
rsv
treatment
combin
fluticason
salmeterol
eosinophil
migrat
lung
characterist
seen
rsvinduc
exacerb
asthma
fluticason
salmeterol
reduc
eosinophil
number
bal
fluid
combin
two
drug
effect
basi
synergi
whether
combin
effect
infant
children
affect
exposur
virus
allergen
unclear
one
import
find
studi
irrespect
frequenc
rsv
infect
fp
combin
therapi
effect
significantli
decreas
ahr
measur
penh
also
studi
mice
infect
twice
rsv
fp
decreas
ahr
fp
alon
result
agreement
previou
report
steroid
alon
found
partial
effect
rsv
infect
viral
induc
asthma
consist
ahr
data
substanti
reduct
pulmonari
inflamm
irrespect
frequenc
rsv
infect
note
experi
mice
sensit
ova
receiv
one
rsv
infect
decreas
eosinophil
increas
lymphocyt
contrast
ovasensit
mice
two
rsv
infect
fp
show
increas
neutrophil
probabl
due
resist
neutrophil
corticosteroid
gener
greater
number
infiltr
neutrophil
repeat
rsv
infect
former
possibl
consist
find
neutrophil
asthma
resist
treatment
fp
suggest
addit
longact
beta
agonist
agent
primarili
affect
recruit
neutrophil
combin
mice
shown
increas
varieti
cytokin
chemokin
includ
rant
macrophag
inflammatori
alpha
eotaxin
mice
singl
infect
show
increas
percentag
cell
perhap
indic
greater
stimul
innat
immun
system
treatment
salmeterol
alon
result
significantli
higher
percentag
cell
characterist
respons
observ
human
infant
suffer
acut
rsv
bronchiol
fp
decreas
number
cytokineproduc
cell
splenocyt
cultur
agreement
increas
number
cell
seen
lung
section
salmeteroltr
mice
mice
infect
twice
rsv
fp
reduc
compar
fp
salmeterol
alon
consist
previou
find
allerg
mice
two
rsv
infect
increas
number
cell
produc
increas
product
associ
recurr
wheez
children
hospit
rsv
bronchiol
anoth
signific
observ
differenti
effect
fp
sal
inflammatori
marker
fp
treatment
caus
increas
express
wherea
sal
show
small
decreas
treatment
combin
result
decreas
express
observ
consist
previou
report
show
fp
combin
decreas
express
human
lung
fibroblast
cell
express
marker
mucu
product
also
decreas
combin
fp
treatment
significantli
either
fp
sal
alon
stain
marker
demonstr
rsvinduc
infiltr
cell
treatment
fp
increas
express
infiltr
lung
fptreat
mice
decreas
contrast
treatment
sal
inhibit
infiltr
combin
fp
treatment
decreas
infiltr
compar
sal
indic
steroid
agonist
differenti
affect
inflammatori
paramet
two
combin
effect
reduc
rsvinduc
lung
inflamm
apoptosi
lymphocyt
lung
characterist
featur
rsv
bronchiol
may
increas
sever
diseas
result
indic
compar
lung
mice
sensit
ova
presenc
absenc
rsv
infect
lung
mice
treat
either
fp
sal
combin
fp
show
decreas
number
apoptot
cell
fp
combin
show
even
fewer
apoptot
cell
compar
fp
sal
alon
suggest
greater
effect
combin
treatment
reason
unclear
may
due
fact
treatment
fp
sal
decreas
infiltr
inflammatori
cell
lung
idea
consist
report
fp
increas
apoptosi
peripher
blood
cell
sal
ova
dapi
tunel
treatment
fp
plu
sal
decreas
lung
inflamm
examin
lung
homogen
rsv
reveal
reduct
viru
titer
mice
treat
fp
suggest
combin
treatment
exert
addit
antivir
effect
measur
bal
fluid
show
increas
product
lung
mice
treat
fp
therapi
thu
observ
reduct
rsv
titer
may
due
increas
level
lung
induc
fp
combin
therapi
although
number
experiment
approach
investig
treatment
rsv
infect
possibl
infect
manag
use
alreadi
avail
therapi
import
find
result
studi
show
ovasensit
mice
receiv
fluticason
plu
salmeterol
signific
reduct
rsvinduc
inflamm
rsv
titer
compar
receiv
drug
individu
result
suggest
use
combin
therapi
effect
reduc
virallyinduc
asthma
exacerb
fp
reduct
rsv
titer
correl
increas
product
figur
fp
reduct
rsv
titer
correl
increas
product
two
group
mice
sensit
ova
prophylact
treat
fp
sal
fp
prior
infect
rsv
three
day
infect
sacrif
homogen
lung
one
group
mice
assay
rsv
titer
bal
fluid
second
group
assay
result
one
repres
experi
two
